{
  "source": "PA-Med-Nec-Cimzia.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 2195-9\nProgram Prior Authorization/Medical Necessity\nMedication Cimzia® (certolizumab)\nP&T Approval Date 5/2020, 5/2021, 6/2021, 12/2021, 5/2022, 5/2023, 7/2023, 10/2024,\n11/2024\nEffective Date 2/1/2025\n1. Background:\nCimzia (certolizumab) is a tumor necrosis factor (TNF) blocker indicated for reducing signs\nand symptoms of Crohn's disease (CD) and maintaining clinical response in adult patients\nwith moderately to severely active disease who have had an inadequate response to\nconventional therapy. Cimzia is also indicated for the treatment of adults with moderately to\nseverely active rheumatoid arthritis (RA), treatment of adult patients with active psoriatic\narthritis (PsA), treatment of adults with active ankylosing spondylitis (SpA), treatment of\nadults with moderate to severe plaque psoriasis (PS) who are candidates for systemic therapy\nor phototherapy, for the treatment of adults with active non-radiographic axial\nspondyloarthritis (nr-axSpA), with objective signs of inflammation, and for the treatment of\nactive polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older.\n2. Coverage Criteriaa:\nA. Crohn’s Disease (CD)\n1. Initial Authorization\na. Cimzia will be approved based on all of the following criteria:\n(1) Diagnosis of moderately to severely active Crohn’s disease\n-AND-\n(2) One of the following:\n(a) History of failure to one of the following conventional therapies at\nmaximally indicated doses, unless contraindicated or clinically significant\nadverse effects are experienced (document drug, date, and duration of trial):\ni. Corticosteroids (e.g., prednisone, methylprednisolone, budesonide)\nii. 6-mercaptopurine (Purinethol)\niii. Azathioprine (Imuran)\niv. Methotrexate (Rheumatrex, Trexall)\n-OR-\n(b) Patient has been previously treated with a targeted immunomodulator FDA-\napproved for the treatment of Crohn’s disease as documented by claims\n© 2024 UnitedHealthc",
    "exate (Rheumatrex, Trexall)\n-OR-\n(b) Patient has been previously treated with a targeted immunomodulator FDA-\napproved for the treatment of Crohn’s disease as documented by claims\n© 2024 UnitedHealthcare Services, Inc.\n1\nhistory or submission of medical records (Document drug, date, and duration\nof therapy) [e.g., adalimumab, Stelara (ustekinumb), Skyrizi (risankizumab)].\n-OR-\n(c) Both of the following:\ni. Patient is currently on Cimzia therapy as documented by claims history or\nsubmission of medical records (Document date and duration of therapy):\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in the\nprescriber’s office, or any form of assistance from the UCB sponsored\nCIMplicity® program (e.g., sample card which can be redeemed at a\npharmacy for a free supply of medication) as a means to establish as a\ncurrent user of Cimzia*\n-AND-\n(3) Patient is not receiving Cimzia in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Simponi (golimumab), Orencia\n(abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib),\nRinvoq (upadacitinib), Stelara (ustekinumab), Skyrizi (risankizumab)]\n-AND-\n(4) Prescribed by or in consultation with a gastroenterologist\n* Patients requesting initial authorization who were established on therapy via the receipt\nof a manufacturer supplied sample at no cost in the prescriber’s office or any form of\nassistance from the UCB sponsored CIMplicity® program shall be required to meet\ninitial authorization criteria as if patient were new to therapy.\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Cimzia will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Cimzia therapy\n-AND-\n(2) Patient is not receiving Cimzia in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Simponi (golimumab), Orencia\n(abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib),\nRinvoq (upadacitinib),",
    "ombination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Simponi (golimumab), Orencia\n(abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib),\nRinvoq (upadacitinib), Stelara (ustekinumab), Skyrizi (risankizumab)]\nAuthorization will be issued for 12 months.\n© 2024 UnitedHealthcare Services, Inc.\n2\nB. Rheumatoid Arthritis (RA)\n1. Initial Authorization\na. Cimzia will be approved based on all of the following criteria:\n(1) Diagnosis of moderately to severely active rheumatoid arthritis\n-AND-\n(2) One of the following:\n(a) History of failure to a 3 month trial of one non-biologic disease modifying\nanti-rheumatic drug (DMARD) [e.g., methotrexate, leflunomide,\nsulfasalazine, hydroxychloroquine] at maximally indicated doses, unless\ncontraindicated or clinically significant adverse effects are experienced\n(document drug, date, and duration of trial)b\n-OR-\n(b) Patient has been previously treated with a targeted immunomodulator FDA-\napproved for the treatment of rheumatoid arthritis as documented by claims\nhistory or submission of medical records (Document drug, date, and duration\nof therapy) [e.g., Enbrel (etanercept), Simponi (golimumab), Orencia\n(abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib),\nRinvoq (upadacitinib)]\n-OR-\n(c) Both of the following:\ni. Patient is currently on Cimzia therapy as documented by claims history or\nsubmission of medical records (Document date and duration of therapy):\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in the\nprescriber’s office, or any form of assistance from the UCB sponsored\nCIMplicity® program (e.g., sample card which can be redeemed at a\npharmacy for a free supply of medication) as a means to establish as a\ncurrent user of Cimzia*\n-AND-\n(3) Patient is not receiving Cimzia in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Simponi (golimumab), Orencia\n(abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitini",
    " not receiving Cimzia in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Simponi (golimumab), Orencia\n(abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib),\nRinvoq (upadacitinib)]\n-AND-\n© 2024 UnitedHealthcare Services, Inc.\n3\n(4) Prescribed by or in consultation with a rheumatologist\n* Patients requesting initial authorization who were established on therapy via the receipt\nof a manufacturer supplied sample at no cost in the prescriber’s office or any form of\nassistance from the UCB sponsored CIMplicity® program shall be required to meet\ninitial authorization criteria as if patient were new to therapy.\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Cimzia will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Cimzia therapy\n-AND-\n(2) Patient is not receiving Cimzia in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Simponi (golimumab), Orencia\n(abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib),\nRinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\nC. Psoriatic Arthritis (PsA)\n1. Initial Authorization\na. Cimzia will be approved based on all of the following criteria:\n(1) Diagnosis of active psoriatic arthritis\n-AND-\n(2) One of the following:\n(a) History of failure to a 3 month trial of methotrexate at maximally indicated\ndose, unless contraindicated or clinically significant adverse effects are\nexperienced (document date and duration of trial)b\n-OR-\n(b) Patient has been previously treated with a targeted immunomodulator\nFDA-approved for the treatment of psoriatic arthritis as documented by\nclaims history or submission of medical records (Document drug, date,\nand duration of therapy) [e.g., Enbrel (etanercept), adalimumab, Simponi\n(golimumab), Orencia (abatacept), Stelara (ustekinumab), Skyrizi\n(risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz\n(ixekizumab), Xeljanz (tofa",
    "nbrel (etanercept), adalimumab, Simponi\n(golimumab), Orencia (abatacept), Stelara (ustekinumab), Skyrizi\n(risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz\n(ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq\n(upadacitinib), Otezla (apremilast)]\n© 2024 UnitedHealthcare Services, Inc.\n4\n-OR-\n(c) Both of the following:\ni. Patient is currently on Cimzia therapy as documented by claims history or\nsubmission of medical records (Document date and duration of therapy):\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in the\nprescriber’s office, or any form of assistance from the UCB sponsored\nCIMplicity® program (e.g., sample card which can be redeemed at a\npharmacy for a free supply of medication) as a means to establish as a\ncurrent user of Cimzia*\n-AND-\n(3) Patient is not receiving Cimzia in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), adalimumab, Simponi\n(golimumab), Orencia (abatacept), Stelara (ustekinumab), Skyrizi\n(risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz\n(ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq\n(upadacitinib), Otezla (apremilast)]\n-AND-\n(4) Prescribed by or in consultation with one of the following:\n(a) Rheumatologist\n(b) Dermatologist\n* Patients requesting initial authorization who were established on therapy via the receipt\nof a manufacturer supplied sample at no cost in the prescriber’s office or any form of\nassistance from the UCB sponsored CIMplicity® program shall be required to meet\ninitial authorization criteria as if patient were new to therapy.\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Cimzia will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Cimzia therapy\n-AND-\n(2) Patient is not receiving Cimzia in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), adalimumab, Simponi\n(golimumab), Orencia (abatacept), ",
    "onse to Cimzia therapy\n-AND-\n(2) Patient is not receiving Cimzia in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), adalimumab, Simponi\n(golimumab), Orencia (abatacept), Stelara (ustekinumab), Skyrizi\n(risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz\n© 2024 UnitedHealthcare Services, Inc.\n5\n(ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq\n(upadacitinib), Otezla (apremilast)]\nAuthorization will be issued for 12 months.\nD. Ankylosing Spondylitis (AS) and non-radiographic Axial Spondyloarthritis (nr-\naxSpA)\n1. Initial Authorization\na. Cimzia will be approved based on all of the following criteria:\n(1) Diagnosis of active ankylosing spondylitis or non-radiographic axial\nspondyloarthritis\n-AND-\n(2) One of the following:\n(a) History of failure to two NSAIDs (e.g., ibuprofen, naproxen) at maximally\nindicated doses, each used for at least 4 weeks, unless contraindicated or\nclinically significant adverse effects are experienced (document drug, date,\nand duration of trials)\n-OR-\n(b) Patient has been previously treated with a targeted immunomodulator\nFDA-approved for the treatment of ankylosing spondylitis as documented\nby claims history or submission of medical records (Document drug,\ndate, and duration of therapy) [e.g., adalimumab, Simponi (golimumab),\nXeljanz/Xeljanz XR (tofacitinib), Rinvoq (upadacitinib)].\n-OR-\n(c) Both of the following:\ni. Patient is currently on Cimzia therapy as documented by claims history or\nsubmission of medical records (Document date and duration of therapy):\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in the\nprescriber’s office, or any form of assistance from the UCB sponsored\nCIMplicity® program (e.g., sample card which can be redeemed at a\npharmacy for a free supply of medication) as a means to establish as a\ncurrent user of Cimzia*\n-AND-\n(3) Patient is not receiving Cimzia in combination with another targeted\nimmunomodulator [e.g., Enbrel (etane",
    "or a free supply of medication) as a means to establish as a\ncurrent user of Cimzia*\n-AND-\n(3) Patient is not receiving Cimzia in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Simponi (golimumab), Orencia\n© 2024 UnitedHealthcare Services, Inc.\n6\n(abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib),\nRinvoq (upadacitinib)]\n-AND-\n(4) Prescribed by or in consultation with a rheumatologist\n* Patients requesting initial authorization who were established on therapy via the receipt\nof a manufacturer supplied sample at no cost in the prescriber’s office or any form of\nassistance from the UCB sponsored CIMplicity® program shall be required to meet\ninitial authorization criteria as if patient were new to therapy.\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Cimzia will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Cimzia therapy\n-AND-\n(2) Patient is not receiving Cimzia in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Simponi (golimumab), Orencia\n(abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib),\nRinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\nE. Plaque Psoriasis (PS)\n1. Initial Authorization\na. Cimzia will be approved based on all of the following criteria:\n(1) Diagnosis of moderate to severe plaque psoriasis\n-AND-\n(2) One of the following:\n(a) All of the following:\ni. Greater than or equal to 3% body surface area involvement, palmoplantar,\nfacial, genital involvement, or severe scalp psoriasis\n-AND-\nii. History of failure to one of the following topical therapies, unless\ncontraindicated or clinically significant adverse effects are experienced\n(document drug, date, and duration of trial):\n© 2024 UnitedHealthcare Services, Inc.\n7\na. Corticosteroids (e.g., betamethasone, clobetasol, desonide)\nb. Vitamin D analogs (e.g., calcitriol, calcipotriene)\nc. Tazarotene\nd. Calcineurin inhi",
    "trial):\n© 2024 UnitedHealthcare Services, Inc.\n7\na. Corticosteroids (e.g., betamethasone, clobetasol, desonide)\nb. Vitamin D analogs (e.g., calcitriol, calcipotriene)\nc. Tazarotene\nd. Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)\ne. Anthralin\nf. Coal tar\n-AND-\niii. History of failure to a 3 month trial of methotrexate at maximally\nindicated dose, unless contraindicated or clinically significant adverse\neffects are experienced (document date and duration of trial)b\n-OR-\n(b) Patient has been previously treated with a targeted immunomodulator\nFDA-approved for the treatment of plaque psoriasis as documented by\nclaims history or submission of medical records (Document drug, date,\nand duration of therapy) [e.g., adalimumab, Otezla (apremilast), Skyrizi\n(risankizumab), Stelara (ustekinumab), Tremfya (guselkumab)].\n-OR-\n(c) Both of the following:\ni. Patient is currently on Cimzia therapy as documented by claims history or\nsubmission of medical records (Document date and duration of therapy):\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in the\nprescriber’s office, or any form of assistance from the UCB sponsored\nCIMplicity® program (e.g., sample card which can be redeemed at a\npharmacy for a free supply of medication) as a means to establish as a\ncurrent user of Cimzia*\n-AND-\n(3) Patient is not receiving Cimzia in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Simponi (golimumab), Orencia\n(abatacept), adalimumab, Stelara (ustekinumab), Skyrizi (risankizumab),\nTremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Siliq\n(brodalumab), Ilumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant\n(baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]\n-AND-\n(4) Prescribed by or in consultation with a dermatologist\n© 2024 UnitedHealthcare Services, Inc.\n8\n* Patients requesting initial authorization who were established on therapy via the receipt\nof a manufacturer supplied sample at no cost in the pr",
    "ermatologist\n© 2024 UnitedHealthcare Services, Inc.\n8\n* Patients requesting initial authorization who were established on therapy via the receipt\nof a manufacturer supplied sample at no cost in the prescriber’s office or any form of\nassistance from the UCB sponsored CIMplicity® program shall be required to meet\ninitial authorization criteria as if patient were new to therapy.\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Cimzia will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Cimzia therapy\n-AND-\n(2) Patient is not receiving Cimzia in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Simponi (golimumab), Orencia\n(abatacept), adalimumab, Stelara (ustekinumab), Skyrizi (risankizumab),\nTremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Siliq\n(brodalumab), Ilumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant\n(baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]\nAuthorization will be issued for 12 months.\nF. Polyarticular Juvenile Idiopathic Arthritis (pJIA)\n1. Initial Authorization\na. Cimzia will be approved based on all of the following criteria:\n(1) Diagnosis of active polyarticular juvenile idiopathic arthritis\n-AND-\n(2) Patient is not receiving Cimzia in combination with another targeted\nimmunomodulator [e.g., adalimumab, Enbrel (etanercept), Simponi\n(golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant\n(baricitinib), Rinvoq (upadacitinib)]\n-AND-\n(3) Prescribed by or in consultation with a rheumatologist\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Cimzia will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Cimzia therapy\n© 2024 UnitedHealthcare Services, Inc.\n9\n-AND-\n(2) Patient is not receiving Cimzia in combination with another targeted\nimmunomodulator [e.g., adalimumab, Enbrel (etanercept), Simponi\n(golimumab), Orencia (abatacept), Xeljanz (tofaci",
    " Inc.\n9\n-AND-\n(2) Patient is not receiving Cimzia in combination with another targeted\nimmunomodulator [e.g., adalimumab, Enbrel (etanercept), Simponi\n(golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant\n(baricitinib), Rinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\nb For Connecticut, Kentucky and Mississippi business only a 30-day trial will be required.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Cimzia [package insert]. Smyrna, GA: UCB, Inc; December 2022.\n2. Ward MM, Deodhar, A, Gensler, LS, et al. 2019 Update of the American College of\nRheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment\nNetwork Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic\nAxial Spondyloarthritis. Arthritis & Rheumatology. 2019; 71(10): 1599-1613.\n3. Yu, DT, van Tubergen A. Treatment of axial spondyloarthritis (ankylosing spondylitis and\nnonradiographic axial spondyloarthritis) in adults. Sieper, J (Ed). UpToDate. Waltham, MA:\nUpToDate Inc. http://www.uptodate.com (Accessed on October 10, 2019.)\n4. Singh, JA, Guyatt, G, et al. 2018 American College of Rheumatology/National Psoriasis\nFoundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis & Rheumatology. 2019;\n71(1): 5-32.\n5. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and\npsoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the tre",
    "71(1): 5-32.\n5. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and\npsoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of\npsoriasis with biologics. J Am Acad Dermatol 2008; 58(5):826-50.\n6. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis\nand psoriatic arthritis. Psoriatic arthritis: Overview and guidelines of care for treatment with an\nemphasis on the biologics. J Am Acad Dermatol 2008;58(5):851-64.\n7. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and\npsoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis\nwith topical therapies. J Am Acad Dermatol 2009;60(4):643-59.\n8. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and\npsoriatic arthritis. Guidelines of care for the treatment of psoriasis with phototherapy and\nphotochemotherapy. J Am Acad Dermatol 2010;62(1):114-35.\n9. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and\npsoriatic arthritis. Guidelines of care for the management and treatment of psoriasis with\ntraditional systemic agents. J Am Acad Dermatol 2009;61(3):451-85.\n© 2024 UnitedHealthcare Services, Inc.\n10\n10. Nast A, et al; European S3-Guidelines on the systemic treatment of psoriasis vulgaris – update\n2015 – short version – EFF in cooperation with EADV and IPC, J Eur Acad Derm Venereol\n2015;29:2277-94.\n11. Menter A, Korman NJ, Elmets CA,Feldman SR, Gelfand JM, Gordon KB, Guidelines of care for\nthe management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment\nof psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J\nAm Acad Dermatol. 2011 Jul;65(1):137-74.\n12. Gossec L, et al; European League Against Rheumatism (EULAR) recommendations for the\nmanagement of psoriatic arthritis with phar",
    "idence-based conclusions. J\nAm Acad Dermatol. 2011 Jul;65(1):137-74.\n12. Gossec L, et al; European League Against Rheumatism (EULAR) recommendations for the\nmanagement of psoriatic arthritis with pharmacological therapies: 2015 update, Ann Rheum Dis\n2016;75:499-510.\n13. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management\nand treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029-72.\n14. Fraenkel L, Bathon JM, et al; 2021 American College of Rheumatology Guideline for the\nTreatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2021 Jul;73(7):924-939.\nProgram Prior Authorization/Medical Necessity - Cimzia (certolizumab)\nChange Control\n5/2020 New Program\n5/2021 Annual review. Removed preceding month requirement from failure\ncriteria. Removed prescriber requirement from reauthorization criteria.\nRemoved drug documentation where only one drug is required.\nReference updated.\n6/2021 Added coverage criteria for patients previously treated with a biologic\nDMARD. Added clarification that submission of medical records is\nrequired documenting previous or current therapy with a biologic\nDMARD in order to bypass step through non-biologic therapies if claim\nhistory not available.\n12/2021 Updated conventional DMARD bypass language for rheumatoid arthritis,\npsoriatic arthritis and psoriasis with no change to clinical intent. Updated\nCT/KY footnote.\n5/2022 Added targeted synthetic DMARD to bypass criteria for AS. Added\nRinvoq and Xeljanz as a JAK inhibitor example where applicable. Added\nMississippi to state mandate.\n5/2023 Annual review. Updated drug examples to mirror other pharmacy\nprograms. Updated reference.\n7/2023 Updated not receiving in combination language to targeted\nimmunomodulator and updated examples.\n10/2024 Annual review. Updated state mandate footnote and reference.\n11/2024 Added coverage criteria for pJIA. Updated background and reference.\n© 2024 UnitedHealthcare Services, Inc.\n11"
  ]
}